Chardan Capital Reiterates Buy Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $38.00 target price on the stock. Chardan Capital’s price objective suggests a potential upside of 92.99% from the stock’s current price.

Several other equities research analysts have also recently weighed in on DYN. Sanford C. Bernstein set a $23.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada lifted their price objective on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Raymond James Financial reissued a “strong-buy” rating and issued a $40.00 price objective on shares of Dyne Therapeutics in a research note on Monday. Finally, JPMorgan Chase & Co. decreased their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, November 14th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Buy” and an average price target of $38.41.

Dyne Therapeutics Stock Up 6.8%

Shares of NASDAQ:DYN opened at $19.69 on Tuesday. The firm has a market cap of $2.81 billion, a P/E ratio of -5.38 and a beta of 1.30. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $28.96. The business has a fifty day simple moving average of $18.91 and a 200 day simple moving average of $14.18. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. Analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 27.6% during the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after acquiring an additional 2,109,257 shares in the last quarter. RA Capital Management L.P. raised its holdings in shares of Dyne Therapeutics by 52.2% in the first quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company’s stock valued at $101,613,000 after purchasing an additional 3,333,248 shares during the last quarter. Atlas Venture Life Science Advisors LLC lifted its position in shares of Dyne Therapeutics by 13.9% during the first quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company’s stock valued at $95,505,000 after purchasing an additional 1,111,111 shares in the last quarter. TCG Crossover Management LLC boosted its holdings in Dyne Therapeutics by 22.5% during the third quarter. TCG Crossover Management LLC now owns 4,615,144 shares of the company’s stock worth $58,382,000 after purchasing an additional 848,484 shares during the last quarter. Finally, Braidwell LP grew its position in Dyne Therapeutics by 431.6% in the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company’s stock worth $37,879,000 after purchasing an additional 2,940,162 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.